

Loris Riccardo Lopetuso

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5146772/loris-riccardo-lopetuso-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88

papers

3,406

citations

30

h-index

57

g-index

98

ext. papers

4,764

ext. citations

4.1

avg, IF

5.49

L-index

#	Paper	IF	Citations
88	Commensal Clostridia: leading players in the maintenance of gut homeostasis. <i>Gut Pathogens</i> , 2013 , 5, 23	5.4	412
87	Proteobacteria: A Common Factor in Human Diseases. <i>BioMed Research International</i> , 2017 , 2017, 9351597		342
86	Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. <i>Nutrients</i> , 2019 , 11,	6.7	171
85	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2019 , 68, 2111-2121	19.2	169
84	Actinobacteria: A relevant minority for the maintenance of gut homeostasis. <i>Digestive and Liver Disease</i> , 2018 , 50, 421-428	3.3	158
83	The gut barrier: new acquisitions and therapeutic approaches. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46 Suppl, S12-7	3	132
82	Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. <i>BioMed Research International</i> , 2013 , 2013, 435268	3	116
81	Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. <i>World Journal of Gastroenterology</i> , 2016 , 22, 5505-11	5.6	91
80	Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease. <i>Frontiers in Immunology</i> , 2013 , 4, 181	8.4	86
79	Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders. <i>Digestive Diseases</i> , 2018 , 36, 56-65	3.2	85
78	European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal [Exit Strategies] in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 17-31	1.5	83
77	Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 152-159	6.1	79
76	Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide. <i>Gastroenterology Research and Practice</i> , 2017 , 2017, 8646495	2	73
75	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. <i>Digestive Diseases</i> , 2016 , 34, 269-78	3.2	72
74	Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals. <i>Digestive and Liver Disease</i> , 2018 , 50, 635-639	3.3	62
73	IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E9362-E9370	11.5	62
72	Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2012 , 5, 18		59

71	The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. <i>European Review for Medical and Pharmacological Sciences</i> , 2015 , 19, 1068-76	2.9	59
70	Gut Microbiota Profiling and Gut-Brain Crosstalk in Children Affected by Pediatric Acute-Onset Neuropsychiatric Syndrome and Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. <i>Frontiers in Microbiology</i> , 2018 , 9, 675	5.7	51
69	Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. <i>World Journal of Gastroenterology</i> , 2015 , 21, 12322-33	5.6	47
68	Bacteriocins and Bacteriophages: Therapeutic Weapons for Gastrointestinal Diseases?. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	47
67	Can We Predict the Efficacy of Anti-TNF- α Agents?. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	43
66	Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders. <i>European Review for Medical and Pharmacological Sciences</i> , 2019 , 23, 8075-8083	2.9	42
65	Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)- α in the Liver. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	35
64	for the Treatment of Acute Diarrhea in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Nutrients</i> , 2018 , 10,	6.7	34
63	Skeletal muscle-gut axis: emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases. <i>Minerva Gastroenterologica E Dietologica</i> , 2018 , 64, 351-362	1.6	34
62	Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease. <i>Liver International</i> , 2020 , 40, 878-888	7.9	32
61	The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	32
60	Role of yeasts in healthy and impaired gut microbiota: the gut mycome. <i>Current Pharmaceutical Design</i> , 2014 , 20, 4565-9	3.3	32
59	Role of microbiota and innate immunity in recurrent Clostridium difficile infection. <i>Journal of Immunology Research</i> , 2014 , 2014, 462740	4.5	31
58	The gastrointestinal microbiome - functional interference between stomach and intestine. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2014 , 28, 995-1002	2.5	30
57	Gut Virome and Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1708-12	4.5	30
56	Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice. <i>Digestive and Liver Disease</i> , 2013 , 45, 1017-21	3.3	29
55	Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma. <i>PLoS ONE</i> , 2020 , 15, e0231789	3.7	28
54	Flexible colonoscopy in mice to evaluate the severity of colitis and colorectal tumors using a validated endoscopic scoring system. <i>Journal of Visualized Experiments</i> , 2013 , e50843	1.6	27

53	Intestinal permeability in physiological and pathological conditions: major determinants and assessment modalities. <i>European Review for Medical and Pharmacological Sciences</i> , 2019 , 23, 795-810	2.9	25
52	Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. <i>United European Gastroenterology Journal</i> , 2020 , 8, 775-781	5.3	23
51	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1306-1314	4.5	22
50	Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis. <i>Transplantation Proceedings</i> , 2016 , 48, 402-7	1.1	22
49	Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for gut barrier protectors in IBD?. <i>United European Gastroenterology Journal</i> , 2014 , 2, 113-22	5.3	21
48	Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center. <i>Nutrients</i> , 2019 , 11,	6.7	20
47	Fecal transplantation for ulcerative colitis: current evidence and future applications. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 343-351	5.4	20
46	COVID-19 and intestinal inflammation: Role of fecal calprotectin. <i>Digestive and Liver Disease</i> , 2020 , 52, 1231-1233	3.3	20
45	Assessment of neurological manifestations in hospitalized patients with COVID-19. <i>European Journal of Neurology</i> , 2020 , 27, 2322-2328	6	19
44	Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin. <i>Mini-Reviews in Medicinal Chemistry</i> , 2015 , 16, 179-85	3.2	17
43	Bacillus clausii and gut homeostasis: state of the art and future perspectives. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 943-8	4.2	16
42	Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2018 , 42, 2313-2325	3.7	16
41	Dietary Magnesium Alleviates Experimental Murine Colitis Through Upregulation of the Transient Receptor Potential Melastatin 6 Channel. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2198-2210	4.5	16
40	The Use of Probiotics in Different Phases of Diverticular Disease. <i>Reviews on Recent Clinical Trials</i> , 2018 , 13, 89-96	1.2	15
39	Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2016 , 34, 202-9	3.2	14
38	Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. <i>Digestive and Liver Disease</i> , 2016 , 48, 391-8	3.3	13
37	Epithelial-specific Toll-like Receptor (TLR)5 Activation Mediates Barrier Dysfunction in Experimental Ileitis. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 392-403	4.5	13
36	Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. <i>PLoS ONE</i> , 2017 , 12, e0186575	3.7	13

35	Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 983-91	4.1	13
34	Gelatin tannate and tyndallized probiotics: a novel approach for treatment of diarrhea. <i>European Review for Medical and Pharmacological Sciences</i> , 2017 , 21, 873-883	2.9	12
33	Gut Microbiota during Dietary Restrictions: New Insights in Non-Communicable Diseases. <i>Microorganisms</i> , 2020 , 8,	4.9	11
32	Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of <i>Akkermansia muciniphila</i> . <i>Digestive and Liver Disease</i> , 2020 , 52, 1002-1010	3.3	10
31	The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 543-551	5.9	9
30	Beyond the HLA Genes in Gluten-Related Disorders. <i>Frontiers in Nutrition</i> , 2020 , 7, 575844	6.2	9
29	Considering gut microbiota disturbance in the management of <i>Helicobacter pylori</i> infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 899-906	4.2	8
28	Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome?. <i>World Journal of Gastroenterology</i> , 2016 , 22, 10198-10209	5.6	8
27	Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for <i>C. difficile</i> infection during the COVID-19 pandemic: A prospective cohort study. <i>Digestive and Liver Disease</i> , 2020 , 52, 1390-1395	3.3	8
26	Microparticles Produced by Activated Platelets Carry a Potent and Functionally Active Angiogenic Signal in Subjects with Crohn's Disease. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	8
25	Anti-tumor necrosis factor therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis. <i>World Journal of Gastroenterology</i> , 2019 , 25, 1465-1477	5.6	7
24	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211006669	4.7	7
23	A novel model of colitis-associated cancer in SAMP1/YitFc mice with Crohn's disease-like ileitis. <i>PLoS ONE</i> , 2017 , 12, e0174121	3.7	6
22	Epidemiology of inflammatory bowel disease in the Republic of San Marino: The "EPIMICI - San Marino" study. <i>Digestive and Liver Disease</i> , 2019 , 51, 218-225	3.3	5
21	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14755	2.9	5
20	Increased abundance is associated with clinical improvement in patients receiving rifaximin treatment. <i>Beneficial Microbes</i> , 2020 , 11, 519-525	4.9	4
19	High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of <i>H. pylori</i> infection. <i>European Review for Medical and Pharmacological Sciences</i> , 2016 , 20, 297-300	2.9	4
18	Infliximab does not increase colonic cancer risk associated to murine chronic colitis. <i>World Journal of Gastroenterology</i> , 2016 , 22, 9727-9733	5.6	3

17	The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center. <i>Endoscopy International Open</i> , 2020 , 8, E980-E984	3	3
16	Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF- α treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 1527-1532	2.2	3
15	Impact of the Trophic Effects of the Secretome From a Multistrain Probiotic Preparation on the Intestinal Epithelia. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 902-913	4.5	3
14	Anti-TNF- α induced psoriasiform lesions in IBD: an abnormal immune activation or a patchy cutaneous immune suppression?. <i>Gut</i> , 2014 , 63, 699-701	19.2	2
13	Winter Is Coming and COVID-19 Vaccine Is Available! The Role of Gastroenterologist in Increasing COVID-19 Vaccine Acceptability Among IBD Patients. <i>Gastroenterology</i> , 2021 , 161, 368-369	13.3	2
12	Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: a multidisciplinary management experience. <i>European Review for Medical and Pharmacological Sciences</i> , 2020 , 24, 564-570	2.9	2
11	Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820968747	4.7	1
10	A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn's disease patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 857-865	4.2	1
9	Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey. <i>Gastroenterology Nursing</i> , 2021 , 44, E59-E66	1	1
8	Epidemiological evaluation of acute gastroenteritis and therapeutic approaches in Middle East Countries. <i>European Review for Medical and Pharmacological Sciences</i> , 2016 , 20, 3891-3901	2.9	1
7	Coeliac disease under a microscope: Histological diagnostic features and confounding factors. <i>Computers in Biology and Medicine</i> , 2019 , 104, 335-338	7	0
6	OP29 ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S021-S022	1.5	
5	P497 IL-33/ST2 levels and gut microbiota characterisation can predict mucosal response to anti-TNF therapy in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S360-S361	1.5	
4	Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: The Picture Is Taking Shape. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 205-206	6.9	
3	Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-8	5.4	
2	A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors. <i>European Review for Medical and Pharmacological Sciences</i> , 2020 , 24, 8469-8476	2.9	
1	Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period. <i>European Review for Medical and Pharmacological Sciences</i> , 2021 , 25, 5826-5835	2.9	20